JP2011523560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523560A5 JP2011523560A5 JP2011512566A JP2011512566A JP2011523560A5 JP 2011523560 A5 JP2011523560 A5 JP 2011523560A5 JP 2011512566 A JP2011512566 A JP 2011512566A JP 2011512566 A JP2011512566 A JP 2011512566A JP 2011523560 A5 JP2011523560 A5 JP 2011523560A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- seq
- xbp
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 145
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 26
- 238000006467 substitution reaction Methods 0.000 claims description 26
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 7
- 102000009016 Cholera Toxin Human genes 0.000 claims description 6
- 108010049048 Cholera Toxin Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108091005601 modified peptides Proteins 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000005865 ionizing radiation Effects 0.000 claims description 3
- 210000004180 plasmocyte Anatomy 0.000 claims description 3
- 229940037003 alum Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 102000008165 X-Box Binding Protein 1 Human genes 0.000 claims 33
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 claims 33
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims 29
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims 29
- 102100032831 Protein ITPRID2 Human genes 0.000 claims 29
- 150000001413 amino acids Chemical class 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 239000003070 absorption delaying agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002612 dispersion medium Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 37
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 35
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 35
- 241000124008 Mammalia Species 0.000 description 23
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 8
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- -1 mechloretamine Chemical compound 0.000 description 6
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 5
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5818008P | 2008-06-02 | 2008-06-02 | |
| US61/058,180 | 2008-06-02 | ||
| PCT/US2009/045866 WO2009149021A2 (en) | 2008-06-02 | 2009-06-01 | Xbp1, cd138, and cs1 peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262194A Division JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523560A JP2011523560A (ja) | 2011-08-18 |
| JP2011523560A5 true JP2011523560A5 (enExample) | 2012-07-05 |
Family
ID=41398806
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512566A Withdrawn JP2011523560A (ja) | 2008-06-02 | 2009-06-01 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017194380A Active JP6438100B2 (ja) | 2008-06-02 | 2017-10-04 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017194380A Active JP6438100B2 (ja) | 2008-06-02 | 2017-10-04 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9096681B2 (enExample) |
| EP (2) | EP2300034B1 (enExample) |
| JP (7) | JP2011523560A (enExample) |
| CN (1) | CN102112147B (enExample) |
| CA (2) | CA2726804C (enExample) |
| WO (1) | WO2009149021A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523560A (ja) | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク． | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| CN105377288B (zh) * | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽的组合物制备药物的用途 |
| ES2820729T3 (es) * | 2013-02-15 | 2021-04-22 | Univ Johns Hopkins | Redirectores de células T específicas de antígenos |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| DE102017207683A1 (de) | 2016-05-09 | 2017-11-09 | Nichia Corporation | Verfahren zur Herstellung eines Nickel-Kobalt-Verbundhydroxids und Verfahren zur Herstellung eines Aktivmaterials einer Positivelektrode für eine wasserfreie Elektrolytsekundärbatterie |
| CN106093393A (zh) * | 2016-06-02 | 2016-11-09 | 滨州医学院 | 一种基于XBP1和XBP1s表达水平的检测胃癌组织的试剂盒 |
| CA3079422A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| CN115040663B (zh) * | 2022-06-15 | 2023-12-12 | 上海交通大学医学院附属仁济医院 | 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU6802801A (en) * | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| US20020164346A1 (en) | 2001-02-14 | 2002-11-07 | Nicolette Charles A. | Altered peptide ligands |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US6979720B2 (en) | 2002-05-03 | 2005-12-27 | E. I. Du Pont De Nemours And Company | manufacture of certain cyclic ester oligomers |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| WO2005037855A2 (en) | 2003-10-17 | 2005-04-28 | Pecos Labs, Inc. | T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same |
| ES2393539T3 (es) | 2004-03-29 | 2012-12-26 | Abbott Biotherapeutics Corp. | Utilización terapéutica de anticuerpos anti-CS1 |
| WO2006028889A2 (en) * | 2004-09-02 | 2006-03-16 | Wyeth | Systems and methods for protein production |
| JP2010500370A (ja) * | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| HUE029027T2 (en) * | 2006-08-07 | 2017-01-30 | Abbvie Biotherapeutics Inc | Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies |
| JP2011523560A (ja) | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク． | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| CN105377288B (zh) | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽的组合物制备药物的用途 |
-
2009
- 2009-06-01 JP JP2011512566A patent/JP2011523560A/ja not_active Withdrawn
- 2009-06-01 CA CA2726804A patent/CA2726804C/en active Active
- 2009-06-01 WO PCT/US2009/045866 patent/WO2009149021A2/en not_active Ceased
- 2009-06-01 US US12/995,661 patent/US9096681B2/en active Active
- 2009-06-01 CN CN200980130349.4A patent/CN102112147B/zh active Active
- 2009-06-01 EP EP09759182.0A patent/EP2300034B1/en active Active
- 2009-06-01 EP EP18162674.8A patent/EP3384919A1/en active Pending
- 2009-06-01 CA CA3138282A patent/CA3138282A1/en active Pending
-
2014
- 2014-12-25 JP JP2014262194A patent/JP6085289B2/ja active Active
-
2015
- 2015-06-29 US US14/754,456 patent/US11083783B2/en active Active
-
2017
- 2017-01-27 JP JP2017013407A patent/JP6224280B2/ja active Active
- 2017-10-04 JP JP2017194380A patent/JP6438100B2/ja active Active
-
2018
- 2018-11-15 JP JP2018214477A patent/JP6796123B2/ja active Active
-
2020
- 2020-11-13 JP JP2020189192A patent/JP7321137B2/ja active Active
-
2021
- 2021-07-08 US US17/370,412 patent/US20220031821A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120931A patent/JP2023134812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022287621B2 (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| US11406692B2 (en) | Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes | |
| JP2011523560A5 (enExample) | ||
| JP6884133B2 (ja) | 志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子 | |
| US20170276681A1 (en) | Methods and compositions for diagnosis and treatment of cancer | |
| EA013876B1 (ru) | Опухолеассоциированные пептиды, беспорядочно связывающиеся с молекулами класса ii человеческого лейкоцитарного антигена (hla) | |
| CN111909278A (zh) | Mhc i类表位递送多肽 | |
| IL309715A (en) | Immunotherapy with A*01 restricted peptides and their combinations against cancer and derived methods | |
| KR20190137858A (ko) | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 | |
| US20240293459A1 (en) | Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use | |
| WO2022109258A1 (en) | Methods and compositions comprising mhc class i peptides | |
| WO2022216856A1 (en) | Methods and compositions comprising mhc class i peptides | |
| US20240100149A1 (en) | Sars-cov-2 constructs, vaccines, and methods | |
| US20240207406A1 (en) | Methods and compositions comprising mhc class i peptides | |
| NL2034658B1 (en) | TIMP3-derived TEIPP neoantigens and uses thereof | |
| EP1709971A1 (en) | Peptide antigens useful for the prophylaxis, treatment and diagnosis of poxvirus infections | |
| Hoffmann et al. | ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses | |
| WO2025117509A1 (en) | Recurrent neoantigen-related peptides and related compositions and methods | |
| HK1165468A (en) | In tumours differentially expressed gene products and use of the same |